Treatment of male stress urinary incontinence with the adjustable male sling ARGUS® in patients with fragile urethra

Ameli G1, Weibl P1, Rutkowski M1, Hübner W1

Research Type

Clinical

Abstract Category

Male Stress Urinary Incontinence (Post Prostatectomy Incontinence)

Abstract 307
Open Discussion ePosters
Scientific Open Discussion Session 22
Friday 9th September 2022
13:25 - 13:30 (ePoster Station 1)
Exhibition Hall
Stress Urinary Incontinence Surgery Male
1. Department of Urology, Teaching Hospital, Clinic of Korneuburg, Austria
In-Person
Presenter
Links

Poster

Abstract

Hypothesis / aims of study
The use of adjustable bulbourethral male slings may be a promising alternative to AUS for the treatment of male stress urinary incontinence (SUI) after prostatic surgery. It is adjustable and does not require manipulation before voiding. 
The Aim of the study was to assess adjustable male sling ARGUS®outcomes in challenging patients with a “fragile urethra” at risk for urethral erosion.
Study design, materials and methods
An institutional retrospective review of all ARGUS® sling placements between March 2005 and September 2020 was performed. A “fragile urethra” was defined as a history of pelvic radiation, previous incontinence surgeries, previous urethroplasty or procedures for bladder neck pathologies. The primary outcome was continence, secondary outcomes included postoperative complications, need for further treatment and patients reported satisfaction. Success was defined as a reduction of more than 50% in pad per day usage (p/d).
Retrograde Leak Point Pressure (RLPP) was measured intraoperatively at baseline (before sling placement), after sling placement and the sling was progressively adjusted by tensioning the silicone columns through the washers. The RLPP was generally adjusted 10-15 cmH2O higher than the reference RLPP measured initially before sling placement.
Results
Within the observation period Argus® sling was indicted in 122 men with moderate to severe urinary incontinence (defined as pad per day usage ≥2) . 69 of 122 patients (56,6%) were identified as having a fragile urethra. 16 patients (23,2%) had a history of pelvic radiation, 23 (33,3%) had a previous incontinence surgery, mostly ProACT Balloons (n=18). In 15 cases (21,7%) prior procedures for bladder neck pathologies were performed and other 15 (21,7%) had multiple risk factors for erosion. The success-rate was reported as 76,5% and  44 patients (63,8%) were socially dry (≤ 1p/d). The p/d improved in average from 3.7 (±1.7) to 1.5 (±1,4) and 90% reported a significant improvement regarding continence and quality of life (QoL). 
Complications included postoperative hematoma (n=4), transient perineal or scrotal pain (n=5), which were treated conservatively. Urethral erosion and infection were reported in 10 cases (erosion n=6 and infection=4). 
Sling explantation was reported in 28 cases after a median of 41 months (range 1.4-164.8 months), mostly associated with persistence urinary incontinence (n=18) or urethral erosion (n=6).
Interpretation of results
Although the higher risk for failure in this cohort of patient,  the success rate with 77% was consistent with the evidence in literature and confirm the effectiveness of Argus® even in men with higher risk for erosion. Patient’s reported satisfaction was 90%, which is at and even above the upper limit in comparison to literature.
Concluding message
The Argus® sling is an effective treatment option to achieve substantial long-term improvement of SUI, even in patients with a high risk for erosion.
References
  1. S S, F V, M F, et al. Argus-T Sling in 182 Male Patients: Short-term Results of a Multicenter Study. Urology. 2017;110.
  2. R B, KJ H, HC G, E B, TS K, BR V. Narrative review of male urethral sling for post-prostatectomy stress incontinence: sling type, patient selection, and clinical applications. Transl Androl Urol. 2021;10(6).
  3. Bauer RM, Rutkowski M, Kretschmer A, Casuscelli J, Stief CG, Huebner W. Efficacy and Complications of the Adjustable Sling System ArgusT for Male Incontinence: Results of a Prospective 2-Center Study. Urology. 2015;85(2):316-320. doi:10.1016/j.urology.2014.10.019
Disclosures
Funding None Clinical Trial No Subjects Human
14/11/2024 03:24:32